<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053161_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134146</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012CO113464</safetyreportid>
		<primarysourcecountry>CO</primarysourcecountry>
		<occurcountry>CO</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121210</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CO113464</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CO</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>MM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19301127</patientbirthdate>
			<patientweight>62</patientweight>
			<patientheight>156</patientheight>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>Pelvic fracture</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Pelvic fracture</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pelvic fracture</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120916</reactionstartdate>
				<reactionfirsttime>362</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fractures (unspecified areas)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fracture</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fracture</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACLASTA</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationnumb>21-817</drugauthorizationnumb>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, annual</drugdosagetext>
				<drugdosageform>Solution For Injection</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Osteoporosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110921</drugstartdate>
				<drugstartperiod>362</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fracture</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fracture</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pelvic fracture</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pelvic fracture</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>BIOCALCIUM</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<actiondrug>4</actiondrug>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CALCIUM</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>CALCIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CO113464, is an initial spontaneous report received from consumer (patient&#8217;s relative) via patient support program &#8220;Aclasta V+S&#8221; on 06 Dec 2012. This report refers to an 81-year-old female patient (ID: 2971). Concomitant medications included Biocalcium and calcium. Treatment with these medications continued. The patient received Aclasta (zoledronic acid) for the treatment of osteoporosis at an unknown dose IV, annual on 21 Sep 2011.  On 16 Sep 2012, patient experienced pelvis fracture and fractures (unspecified areas). During 2012, patient also experienced fractures (unspecified areas). The outcome was unknown. Treatment with Aclasta continued. The events were assessed as serious and not suspected to be related to treatment with Aclasta.</narrativeincludeclinical>
				<sendercomment>Based on review of available reported data does not allow for a proper causality assessment. Reported events (pelvic fracture and fracture) are not assessable with the current data. Pending any new medical information.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
